The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of preoperative concurrent chemoradiotherapy with S-1, irinotecan, and cetuximab for locally advanced rectal adenocarcinoma.
Mitsuyoshi Ota
No relevant relationships to disclose
Ayumu Goto
No relevant relationships to disclose
Yasushi Ichikawa
No relevant relationships to disclose
Yusuke Suwa
No relevant relationships to disclose
Jun Watanabe
No relevant relationships to disclose
Kazuteru Watanabe
No relevant relationships to disclose
Kuniya Tanaka
No relevant relationships to disclose
Hirotoshi Akiyama
No relevant relationships to disclose
Shoichi Fujii
No relevant relationships to disclose
Itaru Endo
No relevant relationships to disclose